News

Published on 25 Feb 2022 on Benzinga

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse...

Article preview image

Here's a roundup of top developments in the biotech space over the last 24 hours.

Lilly & Company, Inc. (NYSE: LLY) announced the U.S. Food and Drug Administration has approved Jardiance, 10 mg, to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. Lilly is co-developing the drug with Boehringer Ingelheim.

Read the rest of the article
NASDAQ.IMGN price evolution
NASDAQ.PLRX price evolution
NASDAQ.PULM price evolution
NASDAQ.BXRX price evolution
NASDAQ.OPK price evolution
NASDAQ.AQST price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc

On September 24, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) marked a significant p...

GuruFocus.com · via Yahoo Finance 1 Oct 2024
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

The market expects Pliant Therapeutics, Inc. (PLRX) to deliver a year-over-year decline in earnin...

Zacks via Yahoo Finance 7 Mar 2024
Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares

Keith Cummings, the CFO of Pliant Therapeutics Inc, sold 9,781 shares of the company on January 1...

GuruFocus.com via Yahoo Finance 22 Jan 2024
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?

Investors are always looking for stocks that are poised to beat at earnings season and Pliant The...

Zacks via Yahoo Finance 10 Nov 2023
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3...

Wall Street expects a year-over-year decline in earnings on higher revenues when Pliant Therapeut...

Zacks via Yahoo Finance 7 Nov 2023
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that ...

Zacks · via Yahoo Finance 27 Oct 2023
Investors in Pliant Therapeutics (NASDAQ:PLRX) have seen splendid returns of...

While Pliant Therapeutics, Inc. (NASDAQ:PLRX) shareholders are probably generally happy, the stoc...

Simply Wall St. · via Yahoo Finance 22 Oct 2023
Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the...

Pliant Therapeutics, Inc. PLRX shares ended the last trading session 14.3% higher at $16.67. The ...

Zacks · via Yahoo Finance 22 Oct 2023
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zac...

Zacks via Yahoo Finance 10 Aug 2023
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zac...

Zacks via Yahoo Finance 10 May 2023

Copyright Statfolio @ 2024

Social Accounts